Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bicycle Therapeutics plc BCYC

Healthcare Biotechnology
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is... see more

Recent & Breaking News (NDAQ:BCYC)

Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire October 18, 2021

Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares

Business Wire October 13, 2021

Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares

Business Wire October 12, 2021

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

Business Wire October 7, 2021

Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Business Wire September 30, 2021

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Business Wire September 1, 2021

Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Business Wire August 5, 2021

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics

Business Wire July 13, 2021

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

PR Newswire July 13, 2021

Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021

Business Wire June 15, 2021

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire May 27, 2021

Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Business Wire May 6, 2021

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

Business Wire April 10, 2021

Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology

Business Wire March 30, 2021

Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors

Business Wire March 18, 2021

Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Business Wire March 11, 2021

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Business Wire March 11, 2021

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs(TM)) in the Journal for ImmunoTherapy of Cancer

Business Wire January 26, 2021

Bicycle Therapeutics Announces Pipeline Progress Update

Business Wire January 14, 2021

Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare Conference

Business Wire November 24, 2020